Sanofi SA (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 241   

Articles published

SNY 57.27 +0.58 (1.02%)
price chart
Sanofi Partners With US-Based Startup For Genetic Heart Disease Drugs
Sanofi SA (ADR) (SNY) announced early Wednesday, its decision to partner with US-based, privately held MyoKardia for the development of first-of-their-kind medicinal therapies designed for individuals suffering from genetic heart diseases.
Related articles »  
Sanofi Still Ahead Of Novo Nordisk In Insulin Drug Race
Novo Nordisk A/S (ADR) (NVO) announced yesterday, that its insulin therapy Tresiba, which was in late-stage trials, has proved to be safe and effective for the treatment of type 1 diabetes in children and young adults.
Related articles »  
Sanofi's Menactra Gets FDA Approval As Booster Vaccine
Sanofi SA (ADR) (SNY) announced yesterday, that it has won the approval of the US Food and Drug Administration (FDA) for a label expansion of its meningococcal vaccine Menactra for use as a booster shot.
Related articles »  
Eli Lilly Gets EC Approval For Biosimilar Version Of Sanofi's Lantus
The new drug is a biosimilar version of Sanofi SA (ADR)'s (SNY) blockbuster insulin glargine Lantus and the first biosimilar insulin to be approved in Europe.
Related articles »  
Sanofi Releases Positive Data For New MS Drug
Sanofi's subsidiary, Genzyme, is working on a Multiple Sclerosis (MS) drug called Lemtrada. Data revealed by the company indicates that the drug has remained effective in patients even after four years of treatment, and has reduced relapse rates as well.
Related articles »  
Sanofi Reports Positive Results For Dengue Vaccine
France based Sanofi SA (ADR) (SNY) announced today that the world's first vaccine against dengue fever, which was in its late stage clinical trials, was able to reduce disease cases by 60.8%.
Related articles »  
Sanofi And Regeneron Announce Positive Results For Cholesterol Drug ...
Sanofi SA (ADR) (SNY) and Regeneron Pharmaceuticals Inc. (REGN) announced over the weekend that their experimental drug Alirocumab significantly cut the level of cholesterol in four trials, indicating that the treatment may prevent heart disease and ...
Related articles »  
Pfizer Takes Lead Over Sanofi With Fast-Track Designation Of Its C. Difficile ...
The designation puts Pfizer ahead of Sanofi SA (ADR) (SNY), which is also developing a similar vaccine. While most forms of the disease can be cured with antibiotics, there currently exists no preventive care for this infection.
Related articles »  
Sanofi, Regeneron Take Lead In Cholestrol Drug Race
Sanofi SA (ADR) (SNY) and Regeneron Pharmaceuticals Inc (REGN) are head-to-head with Amgen, Inc. (AMGN) to introduce the world's first PCSK9 inhibitor in the market.
Related articles »  
Sanofi SA (ADR) (NYSE:SNY) Gets Clearance From The Competition ...
Boston, MA 08/28/2014 (wallstreetpr) - According to reports, Sanofi SA (ADR) (NYSE:SNY) has got the green light from the Competition Commission of India in regard with its proposed purchase deal of an arm of Apollo.